Please login to the form below

Not currently logged in
Email:
Password:

Vedanta Biosciences appoints two new heads

Lisa Schopf and Erik Spek join the firm
Vedanta Biosciences Erik Spek

Vedanta Biosciences has appointed Lisa Schopf as head of preclinical development and Erik Spek as head of intellectual property.

Vedanta is advancing a pipeline of product candidates designed to treat autoimmune, inflammatory and infectious diseases using technology that mines the human microbiome for potent pharmaceutical products.

Schopf formerly served as the senior director of preclinical development at Kala Pharmaceuticals and has over 20 years of industry experience.

Spek joins from Epizyme, a clinical stage biopharmaceutical company focused on epigenetic targets, where he worked as director of intellectual property.

Bernat Olle, CEO of Vedanta Biosciences, said: “We are delighted to welcome Lisa and Erik to the team. This is an exiting time for Vedanta, and their experience and leadership will be invaluable as we advance our pipeline of drug candidates and scale our discovery platform.”

14th October 2015

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Six Degrees Medical Consulting

For over a decade, our medical communication services have helped pharmaceutical companies optimize their brand, disease and corporate objectives. Building...

Latest intelligence

The 2019 WHO essential medicine list: Narrowing the access gap to innovative cancer treatments
The essential medicine list (EML) contains treatments considered to be the most effective and safe in targeting global health concerns. On 9 July 2019, the World Health Organization (WHO) published...
NICE
Evolution or revolution: the latest review of NICE methods
By Leela Barham...
PRO
Integrating patient reported outcomes into clinical trials
How capturing the patient voice is unlocking medicines’ commercial potential...

Infographics